Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.

PropertyValue
has major subject area list Antineoplastic Agents; Janus Kinase 2; Molecular Targeted Therapy; Primary Myelofibrosis; Protein Kinase Inhibitors

Search Criteria
  • Targeted Molecular Therapies